SCHEMBL2889356

SCHEMBL2889356

Cc1c(N2CCN(C(=O)OC(C)C)CC2)nnn1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
HTT P42858 1/20 0.45
TP53 P04637 4/20 0.43
ALOX12 P18054 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
PDK2 Q15119 1/20 0.42
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GRM1 Q13255 2/20 0.40
GRM5 P41594 1/20 0.40
LIPE Q05469 1/20 0.40
SMO Q99835 1/20 0.40
POLB P06746 1/20 0.39
ADRB2 P07550 1/20 0.39
P2RY12 Q9H244 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14582394 0.87 ALDH1A1 (0.53) ALDH1A1HTTTP53ALOX12KMT2A
SCHEMBL5482882 0.84 LIPE (0.44) ALDH1A1KMT2AMEN1PDK2SMN1; SMN2
SCHEMBL2890817 0.84 HTT (0.52) ALDH1A1HTTTP53ALOX12KMT2A
SCHEMBL2889077 0.84 GPR119 (0.52) ALDH1A1TP53LMNAGRM1GRM5
SCHEMBL14582401 0.82 HTT (0.50) ALDH1A1HTTTP53ALOX12KMT2A
SCHEMBL2888999 0.80 GRM5 (0.50) LMNAGRM1GRM5POLB
SCHEMBL2892750 0.77 GAA (0.51) ALDH1A1HTTTP53LMNASMN1; SMN2
SCHEMBL2885002 0.75 GRM1 (0.69) HTTTP53ALOX12GRM1GRM5
SCHEMBL14582539 0.70 HTT (0.43) ALDH1A1HTTTP53ALOX12KMT2A
SCHEMBL11980680 0.70 ALDH1A1 (0.53) ALDH1A1HTTKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858800-B2 Biaryl derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-28 US disclosed
US-7858800-B2 Biaryl derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-28 US disclosed
US-7858800-B2 Biaryl derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-28 US disclosed
US-20070191389-A1 Biaryl derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-16 US disclosed
US-20070191389-A1 Biaryl derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-16 US disclosed
US-20070191389-A1 Biaryl derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-16 US disclosed
EP-1764362-A1 BIARYL DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191389-A1 Biaryl derivatives GRM1, GRIN1, GRIN2B ALDH1A1 712/4885HTT 2050/4885TP53 4862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.